Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity

Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18.
No abstract available

Keywords: bendamustine; chemoimmunotherapy; follicular lymphoma; mitoxantrone; rituximab.

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / adverse effects*
  • Bendamustine Hydrochloride / pharmacology
  • Bendamustine Hydrochloride / therapeutic use
  • Communicable Diseases / etiology*
  • Hematologic Diseases / etiology*
  • Humans
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / pathology
  • Middle Aged
  • Mitoxantrone / adverse effects*
  • Mitoxantrone / pharmacology
  • Mitoxantrone / therapeutic use
  • Rituximab / adverse effects*
  • Rituximab / pharmacology
  • Rituximab / therapeutic use

Substances

  • Rituximab
  • Bendamustine Hydrochloride
  • Mitoxantrone